Why traditional clinical trial quality checks can become reactive, costly, and slow, and how RBQM helps teams focus oversight where risk, data quality, and participant safety matter most.
Why traditional clinical trial quality checks can become reactive, costly, and slow, and how RBQM helps teams focus oversight where risk, data quality, and participant safety matter most.
In this chapter, we look at the traditional approach to clinical trial quality and why it can fall short in modern studies. Historically, quality was often treated as something to be checked retrospectively: comparing source documents with EDC entries, correcting transcription errors, reviewing the Trial Master File late in the study, or addressing protocol issues through amendments after study start.
These checks can still be useful. But when they are used as the primary quality strategy, they can lead to a reactive operating model. Quality is added into the study after the fact, rather than designed into the protocol, processes, and oversight model from the start.
One consequence is the cost of poor quality. Late detection of issues can create delays, rework, unnecessary emails, retraining, frustration across teams, and in more serious cases regulatory findings. Many of these costs are hidden because they accumulate through operational friction rather than appearing as a single visible line item.
The chapter then uses site monitoring as an example. In a traditional model, CRAs may visit sites at a fixed frequency, such as every six weeks. During these visits, a large portion of time may be spent on Source Data Verification, where source documents are compared with what has been entered into EDC. This focuses heavily on detecting transcription errors.
The limitation is that this approach often treats all data as equally important. It can be costly because resources are not focused where they are most needed. It can be slow because data may sit in the system until the next monitoring visit. It can also be incomplete as an oversight model because one CRA may see trends across assigned sites, but not necessarily the full cross-study picture.
Modern trials make this challenge more significant. Studies are more complex, data volumes are higher, more parties are involved, and data increasingly flows from multiple sources beyond traditional EDC. At the same time, data is often available centrally much earlier than a traditional site monitoring model would act on it.
The chapter introduces centralized monitoring as an additional and valuable tool. Centralized monitoring allows teams to review accumulating data from EDC, central labs, imaging, and other sources to detect outliers, trends, and signals earlier.
This leads to the risk-based approach. Risk-based monitoring does not mean the data is not checked. It means checks are targeted and proportionate. Sites may receive more or fewer visits depending on risk, data volume, data quality, anomalies, and trends.
The key message is that RBQM is not about reducing oversight. It is about improving oversight by focusing resources where they can have the greatest impact.
What you will learn in this video
1. Why traditional quality control can become reactive
Retrospective checks can identify problems, but often only after they have already created operational friction, rework, or delay.
2. Why 100% SDV is not the same as better oversight
Source Data Verification can detect transcription errors, but treating all data as equally important can consume significant resources without always improving meaningful trial quality.
3. Why centralized monitoring changes the timing of oversight
When data from EDC, central labs, imaging, and other sources is reviewed centrally, teams can detect outliers, trends, and emerging risk signals earlier.
4. Why risk-based monitoring is not “less monitoring”
RBQM does not remove oversight. It reallocates monitoring effort toward higher-risk sites, critical data, and signals that may affect participant safety, rights, or trial reliability.
5. Why proportionate oversight is now essential
Modern trials are more complex, data-rich, and distributed. A uniform monitoring approach becomes harder to sustain when risks, data flows, and site performance vary across the study.
Why 100% SDV falls short
Traditional site monitoring often follows a fixed visit cadence. A CRA visits an investigative site at a predefined interval, reviews source documents, compares data against what was entered into the EDC system, and checks for transcription errors.
This approach can be familiar and reassuring, but it has clear limitations.
It is costly, because monitoring effort is spread across all sites and all data, regardless of relative importance.
It is slow, because issues may only be detected once enough data has accumulated and a monitoring visit takes place.
It is not always effective, because human review is imperfect and individual monitors may only see part of the overall study pattern.
It is also increasingly difficult to sustain in modern trials, where data comes from many sources, study designs are more complex, and decentralized or hybrid components create additional oversight challenges.
The question is not whether data should be checked. It should. The question is whether every data point should be treated as equally important, or whether oversight should be guided by risk, criticality, and emerging signals.
| Traditional monitoring | Risk-based monitoring |
|---|---|
| Fixed visit frequency | Visits triggered by risk, data volume, data quality, and site signals |
| Broad SDV across large volumes of data | Focus on critical data and critical processes |
| Individual CRA view of assigned sites | Central review across sites to identify outliers and trends |
| Issues may be detected months after data entry | Signals can be reviewed as data becomes available |
| Quality is checked after the fact | Quality is designed, monitored, and adjusted during execution |
| Monitoring effort is distributed uniformly | Oversight effort follows risk and impact |
For sponsors and CROs, this shift has practical implications.
RBQM requires more than changing the monitoring visit schedule. It requires a shared understanding of critical data, critical processes, site risk, centralized review routines, escalation logic, and decision documentation.
For clinical operations teams, RBQM helps distinguish between routine activity and meaningful oversight.
For data management teams, it creates a stronger link between data review, data quality signals, and study conduct.
For QA and compliance teams, it supports a more traceable record of why oversight decisions were made.
For CRAs and site-facing teams, it allows site visits to focus on issues that matter for protocol adherence, participant protection, and reliable trial outcomes.
This video is an educational excerpt from MyRBQM Essentials White Belt, Cyntegrity’s foundation-level training for teams building a shared understanding of QbD, RBQM, risk assessment, monitoring logic, and modern clinical trial oversight.
White Belt is designed for professionals entering RBQM, sponsors and CRO teams preparing for rollout, and clinical staff who need confidence in RBQM terminology and decision cues. This aligns with the current White Belt positioning around shared language, cross-functional alignment, and day-to-day oversight confidence.
Need a quote, speaker, or more info about Cyntegrity? Reach out directly to our media contact for timely assistance.
Industry Solutions
Featured Insights
Start Your Roll-Out
RBQM Capability Pathway
Quick Answers
